{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:41:28Z","timestamp":1793169688114,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019009","name":"Fondation Francophone pour la Recherche sur le Diabete","doi-asserted-by":"crossref","award":["PROBIODIAB 2018"],"award-info":[{"award-number":["PROBIODIAB 2018"]}],"id":[{"id":"10.13039\/100019009","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010115","name":"R\u00e9gion Auvergne-Rh\u00f4ne-Alpes","doi-asserted-by":"crossref","award":["Pack Ambition Recherche 2017"],"award-info":[{"award-number":["Pack Ambition Recherche 2017"]}],"id":[{"id":"10.13039\/501100010115","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["Transversal Program Microbiota"],"award-info":[{"award-number":["Transversal Program Microbiota"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although the mechanism of action of the antidiabetic drug metformin is still a matter of discussions, it is well accepted that the gut plays an important role. To gain more insights into the mechanisms occurring in the different regions of the intestine, adult male mice were fed a high-fat-high sucrose (HFS) diet for 8\u00a0days and treated with metformin by gavage (300\u00a0mg\/day\/kg body weight) during the HFS diet. Metformin counteracted HFS diet-induced overexpression of a network of genes involved in the transport of glucose and fatty acids in the different regions of the small intestine. It also induced beneficial modification of secondary bile acid profile in the caecum, with a reduction of deoxycholic acid and lithocholic acid levels and increased abundance of ursodeoxycholic acid and tauroursodeoxycholic acid, potentially leading to FRX inhibition. In parallel, metformin treatment was associated with specific changes of the microbiota composition in the lumen of the different regions of the intestine. Metformin induced a marked increase in the abundance of\n                    <jats:italic>Akkermansia muciniphila<\/jats:italic>\n                    in the lumen all along the gut and counteracted the effects of HFS diet on the abundances of some bacterial groups generally associated with metabolic disturbances (f-Lachnospiraceae, f-Petostreptococcaceae, g-\n                    <jats:italic>Clostidium<\/jats:italic>\n                    ). Therefore, the present work clearly emphasises the role of all the regions of the intestinal tract in the beneficial action of the antidiabetic drug metformin in a prediabetic mouse model.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-95117-0","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T06:05:02Z","timestamp":1629180302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Metformin treatment for 8\u00a0days impacts multiple intestinal parameters in high-fat high-sucrose fed mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Am\u00e9lie","family":"Bravard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Defois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Makki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Meugnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rainteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rieusset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Godet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"95117_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","volume":"15","author":"M Foretz","year":"2019","unstructured":"Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15, 569\u2013589 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"95117_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fendo.2019.00294","volume":"10","author":"G Vial","year":"2019","unstructured":"Vial, G., Detaille, D. & Guigas, B. Role of mitochondria in the mechanism(s) of action of metformin. Front. Endocrinol. 10, 294 (2019).","journal-title":"Front. Endocrinol."},{"key":"95117_CR3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"RS Hundal","year":"2000","unstructured":"Hundal, R. S. et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49, 2063\u20132069 (2000).","journal-title":"Diabetes"},{"key":"95117_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/00498259409043220","volume":"24","author":"C Wilcock","year":"1994","unstructured":"Wilcock, C. & Bailey, C. J. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiot. Fate Foreign Compd. Biol. Syst. 24, 49\u201357 (1994).","journal-title":"Xenobiot. Fate Foreign Compd. Biol. Syst."},{"key":"95117_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1464-5491.1992.tb01716.x","volume":"9","author":"CF Sum","year":"1992","unstructured":"Sum, C. F. et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet. Med. J. Br. Diabet. Assoc. 9, 61\u201365 (1992).","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"95117_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2337\/dc15-1531","volume":"39","author":"JB Buse","year":"2016","unstructured":"Buse, J. B. et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39, 198\u2013205 (2016).","journal-title":"Diabetes Care"},{"key":"95117_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0006-2952(99)00396-2","volume":"59","author":"T Ikeda","year":"2000","unstructured":"Ikeda, T., Iwata, K. & Murakami, H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem. Pharmacol. 59, 887\u2013890 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"95117_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","volume":"35","author":"E Gontier","year":"2008","unstructured":"Gontier, E. et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur. J. Nucl. Med. Mol. Imaging 35, 95\u201399 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95117_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93936","author":"E Bahne","year":"2018","unstructured":"Bahne, E. et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.93936 (2018).","journal-title":"JCI Insight."},{"key":"95117_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","volume":"63","author":"N-R Shin","year":"2014","unstructured":"Shin, N.-R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727\u2013735 (2014).","journal-title":"Gut"},{"key":"95117_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/dom.13869","volume":"22","author":"DJ Sansome","year":"2020","unstructured":"Sansome, D. J. et al. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes Obes. Metab. 22, 141\u2013148 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"95117_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262\u2013266 (2015).","journal-title":"Nature"},{"key":"95117_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850\u2013858 (2017).","journal-title":"Nat. Med."},{"key":"95117_CR14","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1128\/AEM.01357-14","volume":"80","author":"H Lee","year":"2014","unstructured":"Lee, H. & Ko, G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ. Microbiol. 80, 5935\u20135943 (2014).","journal-title":"Appl. Environ. Microbiol."},{"key":"95117_CR15","doi-asserted-by":"publisher","first-page":"14405","DOI":"10.1038\/srep14405","volume":"5","author":"X Zhang","year":"2015","unstructured":"Zhang, X. et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci. Rep. 5, 14405 (2015).","journal-title":"Sci. Rep."},{"key":"95117_CR16","doi-asserted-by":"publisher","first-page":"E1121","DOI":"10.1152\/ajpendo.00245.2019","volume":"317","author":"A Adeshirlarijaney","year":"2019","unstructured":"Adeshirlarijaney, A., Zou, J., Tran, H. Q., Chassaing, B. & Gewirtz, A. T. Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. Am. J. Physiol. Endocrinol. Metab. 317, E1121\u2013E1130 (2019).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"95117_CR17","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/s41598-019-42531-0","volume":"9","author":"O Horakova","year":"2019","unstructured":"Horakova, O. et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci. Rep. 9, 6156 (2019).","journal-title":"Sci. Rep."},{"key":"95117_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1210\/en.2013-1750","volume":"155","author":"E Harmel","year":"2014","unstructured":"Harmel, E. et al. AMPK in the small intestine in normal and pathophysiological conditions. Endocrinology 155, 873\u2013888 (2014).","journal-title":"Endocrinology"},{"key":"95117_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo, C., Sabb\u00e0, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51\u201369 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"95117_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1507\/endocrj.EJ16-0391","volume":"64","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. The effects of metformin on fibroblast growth factor 19, 21 and fibroblast growth factor receptor 1 in high-fat diet and streptozotocin induced diabetic rats. Endocr. J. 64, 543\u2013552 (2017).","journal-title":"Endocr. J."},{"key":"95117_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","volume":"24","author":"L Sun","year":"2018","unstructured":"Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919\u20131929 (2018).","journal-title":"Nat. Med."},{"key":"95117_CR22","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1210\/jc.2017-01091","volume":"102","author":"A Br\u00f8nden","year":"2017","unstructured":"Br\u00f8nden, A. et al. Single-dose metformin enhances bile acid-induced glucagon-like peptide-1 secretion in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 102, 4153\u20134162 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"95117_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fimmu.2020.00645","volume":"11","author":"J Ouyang","year":"2020","unstructured":"Ouyang, J. et al. The bacterium Akkermansia muciniphila: A sentinel for gut permeability and its relevance to HIV-related inflammation. Front. Immunol. 11, 645 (2020).","journal-title":"Front. Immunol."},{"key":"95117_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cells10010185","volume":"10","author":"C Depommier","year":"2021","unstructured":"Depommier, C. et al. Beneficial effects of akkermansia muciniphila are not associated with major changes in the circulating endocannabinoidome but linked to higher mono-palmitoyl-glycerol levels as new PPAR\u03b1 agonists. Cells 10, 185 (2021).","journal-title":"Cells"},{"key":"95117_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3389\/fmicb.2018.01336","volume":"9","author":"W Ma","year":"2018","unstructured":"Ma, W. et al. Metformin alters gut microbiota of healthy mice: Implication for its potential role in gut microbiota homeostasis. Front. Microbiol. 9, 1336 (2018).","journal-title":"Front. Microbiol."},{"key":"95117_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/microorganisms8040573","volume":"8","author":"M Vacca","year":"2020","unstructured":"Vacca, M. et al. The controversial role of human gut lachnospiraceae. Microorganisms 8, 573 (2020).","journal-title":"Microorganisms"},{"key":"95117_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1264\/jsme2.ME14054","volume":"29","author":"K Kameyama","year":"2014","unstructured":"Kameyama, K. & Itoh, K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ. 29, 427\u2013430 (2014).","journal-title":"Microbes Environ."},{"key":"95117_CR28","doi-asserted-by":"publisher","first-page":"e100778","DOI":"10.1371\/journal.pone.0100778","volume":"9","author":"A Napolitano","year":"2014","unstructured":"Napolitano, A. et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE 9, e100778 (2014).","journal-title":"PLoS ONE"},{"key":"95117_CR29","doi-asserted-by":"publisher","first-page":"1363S","DOI":"10.3945\/jn.109.119784","volume":"140","author":"KDR Setchell","year":"2010","unstructured":"Setchell, K. D. R. & Clerici, C. Equol: Pharmacokinetics and biological actions. J. Nutr. 140, 1363S-S1368 (2010).","journal-title":"J. Nutr."},{"key":"95117_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00253-017-8616-7","volume":"102","author":"K Piwowarek","year":"2018","unstructured":"Piwowarek, K., Lipi\u0144ska, E., Ha\u0107-Szyma\u0144czuk, E., Kieliszek, M. & \u015acibisz, I. Propionibacterium spp.-source of propionic acid, vitamin B12, and other metabolites important for the industry. Appl. Microbiol. Biotechnol. 102, 515\u2013538 (2018).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"95117_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmet.2017.09.019","volume":"27","author":"PV Bauer","year":"2018","unstructured":"Bauer, P. V. et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab. 27, 101\u2013117 (2018).","journal-title":"Cell Metab."},{"key":"95117_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1128\/aem.63.3.1185-1188.1997","volume":"63","author":"KC Doerner","year":"1997","unstructured":"Doerner, K. C., Takamine, F., LaVoie, C. P., Mallonee, D. H. & Hylemon, P. B. Assessment of fecal bacteria with bile acid 7 alpha-dehydroxylating activity for the presence of bai-like genes. Appl. Environ. Microbiol. 63, 1185\u20131188 (1997).","journal-title":"Appl. Environ. Microbiol."},{"key":"95117_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-020-2396-4","volume":"582","author":"M Funabashi","year":"2020","unstructured":"Funabashi, M. et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582, 566\u2013570 (2020).","journal-title":"Nature"},{"key":"95117_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1574-6968.2004.tb09568.x","volume":"235","author":"P Lepercq","year":"2004","unstructured":"Lepercq, P. et al. Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by Clostridium baratii isolated from human feces. FEMS Microbiol. Lett. 235, 65\u201372 (2004).","journal-title":"FEMS Microbiol. Lett."},{"key":"95117_CR35","doi-asserted-by":"publisher","first-page":"31441","DOI":"10.1074\/jbc.M200474200","volume":"277","author":"J Yu","year":"2002","unstructured":"Yu, J. et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem. 277, 31441\u201331447 (2002).","journal-title":"J. Biol. Chem."},{"key":"95117_CR36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI68815","volume":"124","author":"F Lien","year":"2014","unstructured":"Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Investig. 124, 1037\u20131051 (2014).","journal-title":"J. Clin. Investig."},{"key":"95117_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.chemosphere.2018.12.177","volume":"220","author":"D Naville","year":"2019","unstructured":"Naville, D. et al. Chronic exposure to a pollutant mixture at low doses led to tissue-specific metabolic alterations in male mice fed standard and high-fat high-sucrose diet. Chemosphere 220, 1187\u20131199 (2019).","journal-title":"Chemosphere"},{"key":"95117_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jchromb.2012.05.015","volume":"899","author":"L Humbert","year":"2012","unstructured":"Humbert, L. et al. Bile acid profiling in human biological samples: Comparison of extraction procedures and application to normal and cholestatic patients. J. Chromatogr. B Anal. Technol. Biomed. Life. Sci. 899, 135\u2013145 (2012).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"95117_CR39","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852\u2013857 (2019).","journal-title":"Nat. Biotechnol."},{"key":"95117_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11390-010-9306-4","volume":"25","author":"JC Wooley","year":"2009","unstructured":"Wooley, J. C. & Ye, Y. Metagenomics: Facts and artifacts, and computational challenges. J. Comput. Sci. Technol. 25, 71\u201381 (2009).","journal-title":"J. Comput. Sci. Technol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95117-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:35:47Z","timestamp":1670052947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95117-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95117"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95117-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-346051\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16684"}}